OncoTargets and Therapy (Jun 2018)

Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report

  • Li A,
  • Sun S,
  • Song T,
  • Li X,
  • Cheng W,
  • Yao R,
  • Zhang D,
  • Cai Z,
  • Zhang J,
  • Zhai D,
  • Yu C

Journal volume & issue
Vol. Volume 11
pp. 3705 – 3711

Abstract

Read online

Anji Li,1,2,* Shuai Sun,2,* Tao Song,3 Xi Li,2 Wen Cheng,2 Ruipin Yao,2 Danying Zhang,2 Zailong Cai,4 Jie Zhang,5 Dongxia Zhai,2 Chaoqin Yu2 1Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People’s Republic of China; 2Department of Gynecology of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, People’s Republic of China; 3Department of Radiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, People’s Republic of China; 4Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai 200433, People’s Republic of China; 5Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, People’s Republic of China *These authors contributed equally to this work Background: Ovarian adenosquamous carcinoma is an extremely rare type of ovarian histology. Platinum-refractory disease is also uncommon, but can be fatal because of the lack of available treatment options. To date, there is no study or case report on platinum-refractory ovarian adenosquamous carcinoma or its relevant treatment. Case presentation: Herein, we report the case of a 38-year-old Chinese woman with platinum-refractory advanced ovarian adenosquamous carcinoma who received clinical benefit from poly adenosine diphosphate ([ADP] ribose) polymerase and programmed death-1 inhibitors after failure of prior multiline chemotherapies and antiangiogenic agents. The targeted therapy and immunotherapy-controlled disease deterioration and improved performance status. Thus far, the patient has survived longer than 15 months, and she is taking nivolumab as maintenance treatment. Conclusion: Targeted therapy and immunotherapy may be options for rare categories of ovarian cancer, but this warrants more clinical evidence of efficacy and toxicity. Keywords: ovarian adenosquamous carcinoma, platinum-refractory, olaparib, nivolumab, pembrolizumab

Keywords